{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:29Z","timestamp":1793382989542,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In recent years, semaglutide has repeatedly attracted attention in the press and on social media due to its effects in weight management. The social media hype led to off-label use and global supply shortages. Our goal was to identify differences in the presentation of semaglutide on individual social media platforms. Additionally, we aim to investigate the mentioning of various aspects such as adverse drug reactions, drug indications, supply shortages, and costs. Current social media trends regarding semaglutide were also included in the analysis. We collected semaglutide-related posts from the social media platforms Instagram, TikTok, X, Facebook, and YouTube. The posts were then analysed and compared with the adverse drug reactions presented in the STEP trials. Semaglutide was presented by social media users almost exclusively for weight reduction. Misrepresentation of the pharmacological properties of semaglutide with respect to mechanism of action, indication, adverse effects, and drug interactions was very common on social media. The important aspect of treatment costs and supply shortages was barely covered, if at all. Most content creators on Instagram and TikTok were female semaglutide users without medical knowledge. Strikingly, the very common gastrointestinal problems during semaglutide therapy were not even mentioned on Instagram. Some of the posts found under the hashtag \u201cozempic\u201d advertised products that did not contain semaglutide. Violations of the Medicinal Products Act were also identified. Videos of weight loss results have a high probability of artificial intelligence (AI) modification, which can lead to user deception. Social media often provides misleading information, especially regarding drug indications and adverse drug reactions. YouTube has emerged as the most reputable platform for medical information, whereas Instagram provides the least medical knowledge. Misinformation and AI-modified videos can negatively impact the self-perception of young social media users, leading to unreflected medication use.<\/jats:p>","DOI":"10.1007\/s00210-025-04403-5","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T06:12:35Z","timestamp":1752905555000},"page":"815-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Misrepresentation of semaglutide in social media"],"prefix":"10.1007","volume":"399","author":[{"given":"Lara Elisabeth","family":"Propfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"4403_CR1","unstructured":"Apovian CM (2016) Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. Jun;22(7 Suppl):s176\u201385. PMID: 27356115"},{"key":"4403_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bpobgyn.2020.06.006","volume":"70","author":"E Attali","year":"2021","unstructured":"Attali E, Yogev Y (2021) The impact of advanced maternal age on pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 70:2\u20139. https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.06.006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"6","key":"4403_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/13813455.2023.2258559","volume":"130","author":"M Araj-Khodaei","year":"2024","unstructured":"Araj-Khodaei M, Ayati MH, Azizi Zeinalhajlou A, Novinbahador T, Yousefi M, Shiri M, Mahmoodpoor A, Shamekh A, Namazi N, Sanaie S (2024) Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review. Arch Physiol Biochem 130(6):678\u2013685. https:\/\/doi.org\/10.1080\/13813455.2023.2258559","journal-title":"Arch Physiol Biochem"},{"key":"4403_CR4","doi-asserted-by":"publisher","unstructured":"Benamor M, Luca S, Bouguila J, Grosu OM, Avadani BM, Moraru DC, Pertea M (2024) Social media platforms and photo editing applications influence cosmetic surgery choices - literature systematic review and prospective study. MDPI.\u00a0https:\/\/doi.org\/10.3390\/cosmetics11030096","DOI":"10.3390\/cosmetics11030096"},{"issue":"5","key":"4403_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","volume":"25","author":"A Bikou","year":"2024","unstructured":"Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C (2024) A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother 25(5):611\u2013619. https:\/\/doi.org\/10.1080\/14656566.2024.2343092","journal-title":"Expert Opin Pharmacother"},{"key":"4403_CR6","unstructured":"Borsch J (2024) DAZ Ozempic und Wegovy: Ein Wirkstoff, zwei Preise. Accessed: 2025, 27. February. https:\/\/www.deutsche-apotheker-zeitung.de\/news\/artikel\/2023\/07\/18\/ozempic-und-wegovy-ein-wirkstoff-zwei-preise-nbsp"},{"issue":"5","key":"4403_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/biomedicines12051124","volume":"12","author":"A Butuca","year":"2024","unstructured":"Butuca A, Dobrea CM, Arseniu AM, Frum A, Chis AA, Rus LL, Ghibu S, Juncan AM, Muntean AC, Laz\u0103r AE, Gligor FG, Morgovan C, Vonica-Tincu AL (2024) An assessment of semaglutide safety based on real world data: from popularity to spontaneous reporting in eudravigilance database. Biomedicines 12(5):1124. https:\/\/doi.org\/10.3390\/biomedicines12051124","journal-title":"Biomedicines"},{"key":"4403_CR8","doi-asserted-by":"publisher","first-page":"117646","DOI":"10.1016\/j.socscimed.2024.117646","volume":"366","author":"PA Campos-Rivera","year":"2025","unstructured":"Campos-Rivera PA, Alfaro-Ponce B, Ram\u00edrez-P\u00e9rez M, Bernal-Serrano D, Contreras-Loya D, Wirtz VJ (2025) Quality of information and social norms in Spanish-speaking TikTok videos as levers of commercial practices: The case of semaglutide. Soc Sci Med 366:117646. https:\/\/doi.org\/10.1016\/j.socscimed.2024.117646","journal-title":"Soc Sci Med"},{"issue":"1","key":"4403_CR9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.36849\/JDD.7613","volume":"23","author":"A Carboni","year":"2024","unstructured":"Carboni A, Woessner S, Martini O, Marroquin NA, Waller J (2024) Natural weight loss or \u201cozempic face\u201d: demystifying a social media phenomenon. J Drugs Dermatol 23(1):1367\u20131368. https:\/\/doi.org\/10.36849\/JDD.7613","journal-title":"J Drugs Dermatol"},{"issue":"18","key":"4403_CR10","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.3390\/jcm12185921","volume":"12","author":"E Carmina","year":"2023","unstructured":"Carmina E, Longo RA (2023) Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J Clin Med 12(18):5921. https:\/\/doi.org\/10.3390\/jcm12185921","journal-title":"J Clin Med"},{"key":"4403_CR11","unstructured":"DBL-diabetes. (2022). Diabetes Typ 1 und 2: Zahlen weltweit. Accessed: 2025, 22 March https:\/\/www.dbl-diabetes.de\/alles-uber-diabetes\/gesellschaft\/diabetes-typ-1-weltweit"},{"issue":"74","key":"4403_CR12","doi-asserted-by":"publisher","first-page":"102726","DOI":"10.1016\/j.eclinm.2024.102726","volume":"10","author":"R De Giorgi","year":"2024","unstructured":"De Giorgi R, Koychev I, Adler AI, Cowen PJ, Harmer CJ, Harrison PJ, Taquet M (2024) 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. EClinicalMedicine 10(74):102726. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102726","journal-title":"EClinicalMedicine"},{"key":"4403_CR13","unstructured":"Deutsches \u00c4rzteblatt. (2024) Ozempic-Engp\u00e4sse mindestens bis Jahresende. Accessed: 2025, 27 February. https:\/\/www.aerzteblatt.de\/news\/ozempic-engpaesse-mindestens-bis-jahresende-fdcb7c12-db0e-4d32-bef9-857e5b2b5f54"},{"key":"4403_CR14","unstructured":"Dicheva-Radev S, K\u00f6berle U, Dathe K, Klinge A. (2024). Arzneimittelkommission der deutschen \u00c4rzteschaft. \u201cOzempic-Babys\u201d? - was sagt die Datenlage. Accessed: 2025, 25 March https:\/\/www.akdae.de\/arzneimitteltherapie\/arzneiverordnung-in-der-praxis\/ausgaben-archiv\/ausgaben-ab2015\/ausgabe\/artikel?tx_lnsissuearchive_articleshow%5Baction%5D=show&tx_lnsissuearchive_articleshow%5Barticle%5D=6641&tx_lnsissuearchive_articleshow%5Bcontroller%5D=Article&tx_lnsissuearchive_articleshow%5Bissue%5D=39&tx_lnsissuearchive_articleshow%5Byear%5D=2024&cHash=bc7c366ee28b13d692266f224c2e6c6d"},{"key":"4403_CR15","unstructured":"Dixon SJ. (2024). Statista. Social media - statistics & facts. Accessed: 2025, 16 March https:\/\/www.statista.com\/topics\/1164\/social-networks\/#topicOverview"},{"key":"4403_CR16","unstructured":"Duarte F. (2025). Exploding topics. X (Formerly Twitter) User age, gender, & demographic stats (2024). Accessed: 2025, 27 February. https:\/\/explodingtopics.com\/blog\/x-user-stats"},{"issue":"20","key":"4403_CR17","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M (2023) Obesity management in adults: a review. JAMA. 330(20):2000\u20132015. https:\/\/doi.org\/10.1001\/jama.2023.19897","journal-title":"JAMA."},{"key":"4403_CR18","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, J\u00f3dar E, Kandler K, Rigas G, Wadden TA, Wharton S (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28:2083\u20132091. https:\/\/doi.org\/10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"issue":"2","key":"4403_CR19","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.20197","volume":"39","author":"H Godfrey","year":"2025","unstructured":"Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R (2025) Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 39(2):e153\u2013e154. https:\/\/doi.org\/10.1111\/jdv.20197","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"4403_CR20","unstructured":"Graham G (2022) YouTube Official Blog. YouTube Health: Zugang zu zuverl\u00e4ssigen Gesundheitsinformationen. Accessed: 2025, 27 February. https:\/\/blog.youtube\/intl\/de-de\/news-and-events\/youtube-health-zugang-zu-zuverlassigen-gesundheitsinformationen\/"},{"issue":"2","key":"4403_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/dom.16042","volume":"27","author":"N Gregori\u010d","year":"2025","unstructured":"Gregori\u010d N, \u0160ikonja J, Jane\u017e A, Jensterle M (2025) Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism. Diabetes Obes Metab 27(2):519\u2013528. https:\/\/doi.org\/10.1111\/dom.16042","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"4403_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00223-023-01150-8","volume":"114","author":"J Herrou","year":"2024","unstructured":"Herrou J, Mabilleau G, Lecerf JM, Thomas T, Biver E, Paccou J (2024) Narrative review of effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity. Calcif Tissue Int 114(2):86\u201397. https:\/\/doi.org\/10.1007\/s00223-023-01150-8","journal-title":"Calcif Tissue Int"},{"key":"4403_CR23","doi-asserted-by":"publisher","unstructured":"Jafar AB, Jacob J, Kao WK, Ho T (2024) Soft tissue facial changes following massive weight loss secondary to medical and surgical bariatric interventions: a systematic review. Aesthet Surg J Open Forum 6:ojae069\u00a0https:\/\/doi.org\/10.1093\/asjof\/ojae069","DOI":"10.1093\/asjof\/ojae069"},{"issue":"6","key":"4403_CR24","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.3390\/ijerph18062880","volume":"18","author":"B Jiotsa","year":"2021","unstructured":"Jiotsa B, Naccache B, Duval M, Rocher B, Grall-Bronnec M (2021) Social media use and body image disorders: association between frequency of comparing one\u2019s own physical appearance to that of people being followed on social media and body dissatisfaction and drive for thinness. Int J Environ Res Public Health 18(6):2880. https:\/\/doi.org\/10.3390\/ijerph18062880","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"4403_CR26","doi-asserted-by":"publisher","first-page":"e78314","DOI":"10.7759\/cureus.78314","volume":"17","author":"A Khajuria","year":"2025","unstructured":"Khajuria A, Gandotra A, Khajuria A, Arora K, Gupta RK, Gupta U, Babber S (2025) Role of social media in the rising body dissatisfaction and dysmorphia among adolescents. Cureus 17(1):e78314. https:\/\/doi.org\/10.7759\/cureus.78314","journal-title":"Cureus"},{"issue":"10","key":"4403_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"12","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J (2019) The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 12(10):155. https:\/\/doi.org\/10.3389\/fendo.2019.00155","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"13","key":"4403_CR28","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.3390\/ijms25137342","volume":"25","author":"A Koceva","year":"2024","unstructured":"Koceva A, Herman R, Janez A, Rakusa M, Jensterle M (2024) Sex- and gender-related differences in obesity: from pathophysiological mechanisms to clinical implications. Int J Mol Sci 25(13):7342. https:\/\/doi.org\/10.3390\/ijms25137342","journal-title":"Int J Mol Sci"},{"key":"4403_CR29","doi-asserted-by":"publisher","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kitzman DW, Lindegaard ML, M\u00f8ller DV, Shah SJ, Treppendahl MB, Verma S, Abhayaratna W, Ahmed FZ, Chopra V, Ezekowitz J, Fu M, Ito H, Lelonek M, Melenovsky V, Merkely B, N\u00fa\u00f1ez J, Perna E, Schou M, Senni M, Sharma K, Van der Meer P, von Lewinski D, Wolf D, Petrie MC (2023) STEP-HFpEF trial committees and investigators. semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389(12):1069\u20131084. https:\/\/doi.org\/10.1056\/NEJMoa2306963","DOI":"10.1056\/NEJMoa2306963"},{"key":"4403_CR30","unstructured":"Krah ES (2024) Springer Professional. Social-Media-Nutzung in Deutschland sinkt. Accessed: 2025, 22 March. https:\/\/www.springerprofessional.de\/social-media\/kommunikation\/social-media-nutzung-sinkt\/27333640"},{"key":"4403_CR31","doi-asserted-by":"publisher","unstructured":"Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D (2020) Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. obesity (silver spring)\u00a0 28(6):1050\u20131061. https:\/\/doi.org\/10.1002\/oby.22794","DOI":"10.1002\/oby.22794"},{"issue":"7","key":"4403_CR32","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.2196\/jmir.4304","volume":"17","author":"J Lardon","year":"2015","unstructured":"Lardon J, Abdellaoui R, Bellet F, Asfari H, Souvignet J, Texier N, Jaulent MC, Beyens MN, Burgun A, Bousquet C (2015) Adverse drug reaction identification and extraction in social media: a scoping review. J Med Internet Res 17(7):e171. https:\/\/doi.org\/10.2196\/jmir.4304","journal-title":"J Med Internet Res"},{"issue":"1","key":"4403_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-8587(17)30186-9","volume":"6","author":"N Lascar","year":"2018","unstructured":"Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S (2018) Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol 6(1):69\u201380. https:\/\/doi.org\/10.1016\/S2213-8587(17)30186-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4403_CR34","unstructured":"Leimbach A (2023) Tagesschau. Eli Lilly will Abnehmspritze in Deutschland herstellen. Accessed: 2025, 27 February. https:\/\/www.tagesschau.de\/wirtschaft\/lilly-abnehmspritze-deutschland-100.html"},{"key":"4403_CR35","doi-asserted-by":"publisher","unstructured":"Losorelli\u00a0S, Kandathil CK, Saltychev\u00a0M, Wei\u00a0EX, Rossi-Meyer\u00a0MK, Most\u00a0SP (2025) Association between symptoms of body dysmorphia and social media usage: a cross-generational comparison. Facial Plast Surg Aesthet Med. https:\/\/doi.org\/10.1089\/fpsam.2024.0230","DOI":"10.1089\/fpsam.2024.0230"},{"key":"4403_CR36","unstructured":"Martin M (2024) Deutsches \u00c4rzteblatt. Semaglutid: Abnehmmedikamente als Lifestyle?. Accessed: 2025, 17 March. https:\/\/www.aerzteblatt.de\/archiv\/semaglutid-abnehmmedikamente-als-lifestyle-552e544e-0ab9-4d97-a24f-06ac04eb17d8"},{"key":"4403_CR37","doi-asserted-by":"publisher","first-page":"108079","DOI":"10.1016\/j.visres.2022.108079","volume":"199","author":"ML Moshel","year":"2022","unstructured":"Moshel ML, Robinson AK, Carlson TA, Grootswagers T (2022) Are you for real? Decoding realistic AI-generated faces from neural activity. Vision Res 199:108079. https:\/\/doi.org\/10.1016\/j.visres.2022.108079","journal-title":"Vision Res"},{"key":"4403_CR38","unstructured":"Novo Nordisk (2018) Ozempic\u00ae (semaglutide) approved in the EU for the treatment of type 2 diabetes. Accessed: 2025, 17 March. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/attachment.news.eu.nasdaq.com\/a62fda728be380db8c897dc488f48abbc&ved=2ahUKEwjQy9DL3pGMAxVARfEDHVkJFfIQFnoECEgQAQ&usg=AOvVaw0gYUO8juvxMOkUORE26Lps"},{"issue":"1","key":"4403_CR39","doi-asserted-by":"publisher","first-page":"e5516","DOI":"10.1097\/GOX.0000000000005516","volume":"12","author":"ES O\u2019Neill","year":"2024","unstructured":"O\u2019Neill ES, Wiegmann AL, Parrella N, Pittman T, Hood K, Kurlander D (2024) Injectable weight loss medications in plastic surgery: what we know, perioperative considerations, and recommendations for the future. Plast Reconstr Surg Glob Open 12(1):e5516. https:\/\/doi.org\/10.1097\/GOX.0000000000005516","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"15","key":"4403_CR40","doi-asserted-by":"publisher","first-page":"1394506","DOI":"10.3389\/fendo.2024.1394506","volume":"2","author":"P Pantanetti","year":"2024","unstructured":"Pantanetti P, Cangelosi G, Alberti S, Di Marco S, Michetti G, Cerasoli G, Di Giacinti M, Coacci S, Francucci N, Petrelli F, Ambrosio G, Grinta R (2024) Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice. Front Endocrinol (Lausanne) 2(15):1394506. https:\/\/doi.org\/10.3389\/fendo.2024.1394506","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4403_CR41","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.3390\/cimb46120872","volume":"46","author":"I Papakonstantinou","year":"2024","unstructured":"Papakonstantinou I, Tsioufis K, Katsi V (2024) Spotlight on the mechanism of action of semaglutide. Curr Issues Mol Biol 46:14514\u201314541. https:\/\/doi.org\/10.3390\/cimb46120872","journal-title":"Curr Issues Mol Biol"},{"key":"4403_CR42","doi-asserted-by":"publisher","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R (2024) FLOW trial committees and investigators. effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391(2):109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","DOI":"10.1056\/NEJMoa2403347"},{"key":"4403_CR43","unstructured":"Pharmazeutische Zeitung (2015) Adipositas: Liraglutid zum Abnehmen zugelassen. Accessed: 2025, 07 February. https:\/\/www.pharmazeutische-zeitung.de\/2015-03\/adipositas-liraglutid-zum-abnehmen-zugelassen\/#:~:text=Die%20EU%2DKommission%20hat%20dem,in%20Kombination%20mit%20anderen%20Antidiabetika"},{"key":"4403_CR44","unstructured":"Radtke R (2025) Statista daily data. Adipositaspr\u00e4valenz unter Erwachsenen in den USA nach Alterund Geschlecht 2023. Accessed: 2025, 22 March. https:\/\/de.statista.com\/statistik\/daten\/studie\/73813\/umfrage\/uebergewichtfettleibigkeit-in-den-usa-ausgewaehlte-us-bundesstaaten-2008\/"},{"issue":"7","key":"4403_CR45","doi-asserted-by":"publisher","first-page":"100080","DOI":"10.1016\/j.obpill.2023.100080","volume":"20","author":"J Richards","year":"2023","unstructured":"Richards J, Bang N, Ratliff EL, Paszkowiak MA, Khorgami Z, Khalsa SS, Simmons WK (2023) Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obes Pillars 20(7):100080. https:\/\/doi.org\/10.1016\/j.obpill.2023.100080","journal-title":"Obes Pillars"},{"key":"4403_CR46","unstructured":"Rote Liste (2024a) Byetta\u00ae. Accessed: 2025, 07 February. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/www.fachinfo.de\/fi\/pdf\/010031\/byetta-r&ved=2ahUKEwjGlrHelbGLAxWUBtsEHfHOLREQFnoECBsQAQ&usg=AOvVaw00UDr3CphKoIgDVgoPfTXt"},{"key":"4403_CR47","unstructured":"Rote Liste (2024b) Ozempic\u00ae. Accessed: 2025, 06 February. https:\/\/www.fachinfo.de\/fi\/detail\/022298\/ozempic-r"},{"key":"4403_CR48","unstructured":"Rote Liste (2024c) Rybelsus\u00ae. Accessed: 2025, 09 February. https:\/\/www.fachinfo.de\/fi\/detail\/025034\/rybelsus-r-1-5-4-9-mg"},{"key":"4403_CR49","unstructured":"Rote Liste (2024d) Wegovy\u00ae. Accessed: 2025, 13 March. https:\/\/www.fachinfo.de\/fi\/detail\/023614\/wegovy-r"},{"key":"4403_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA 325:1\u201312. https:\/\/doi.org\/10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"4403_CR51","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA 327:138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"issue":"6","key":"4403_CR52","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/07853890410035296","volume":"36","author":"AK Schr\u00f6der","year":"2004","unstructured":"Schr\u00f6der AK, Tauchert S, Ortmann O, Diedrich K, Weiss JM (2004) Insulin resistance in patients with polycystic ovary syndrome. Ann Med 36(6):426\u201339. https:\/\/doi.org\/10.1080\/07853890410035296","journal-title":"Ann Med"},{"key":"4403_CR53","unstructured":"Schubert Y (2024) Berliner Zeitung. Fragw\u00fcrdige ,,Fett-Weg-Spritze\u201d: Wie das Ozempic Face die Promiwelt erobert. Accessed: 2025, 25 March https:\/\/www.berliner-zeitung.de\/panorama\/robbie-williams-jessica-simpson-sharon-osbourne-wie-das-ozempic-face-hollywood-erobert-li.2207792"},{"key":"4403_CR54","unstructured":"Siebenand S (2023) Pharmazeutische Zeitung. Tirzepatid jetzt auch bei Adipositas zugelassen. Accessed: 2025, 06 February. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/www.pharmazeutische-zeitung.de\/tirzepatid-jetzt-auch-bei-adipositas-zugelassen-144491\/&ved=2ahUKEwihssn9hbCLAxWtB9sEHZObI60QFnoECDoQAQ&usg=AOvVaw3a0EVDqXkcEYibAaoehvrw"},{"key":"4403_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jim-2021-001952","volume":"70","author":"G Singh","year":"2021","unstructured":"Singh G, Krauthamer M, Bjalme-Evans M (2021) Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med 70:5\u201313. https:\/\/doi.org\/10.1136\/jim-2021-001952","journal-title":"J Investig Med"},{"key":"4403_CR56","doi-asserted-by":"publisher","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","volume":"12","author":"MM Smits","year":"2021","unstructured":"Smits MM, Van Raalte DH (2021) Safety of Semaglutide. Front Endocrinol (Lausanne) 12:645563. https:\/\/doi.org\/10.3389\/fendo.2021.645563","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4403_CR57","unstructured":"Statista Research Department (2025a) Social Networks mit den meisten nutzern weltweit 2025. statista daily data. https:\/\/de.statista.com\/statistik\/daten\/studie\/181086\/umfrage\/die-weltweit-groessten-social-networks-nach-anzahl-der-user\/. Accessed\u00a0 03 June\u00a02025"},{"key":"4403_CR58","unstructured":"Statista Research Department (2025b) Gender distribution of active social media users worldwide, by platform. statista daily data. https:\/\/www.statista.com\/statistics\/274828\/gender-distribution-of-active-social-media-users-worldwide-by-platform\/. Accessed 03 June 2025"},{"key":"4403_CR59","unstructured":"Stewart J (2025) BPharm. Ozempic FDA approval history. Accessed: 2025, 17 March. https:\/\/www.drugs.com\/history\/ozempic.html"},{"issue":"2","key":"4403_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15605\/jafes.037.02.14","volume":"37","author":"HC Tan","year":"2022","unstructured":"Tan HC, Dampil OA, Marquez MM (2022) Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc 37(2):65\u201372. https:\/\/doi.org\/10.15605\/jafes.037.02.14","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"4403_CR61","unstructured":"U.S. National Library of Medicine - MedlinePlus Drugs (2024) Herbs and Supplements: Berberine. Accessed: 2025, 23 March https:\/\/medlineplus.gov\/druginfo\/natural\/1126.html"},{"key":"4403_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O\u2019Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 325:1\u201311. https:\/\/doi.org\/10.1001\/jama.2021.1831","journal-title":"JAMA."},{"key":"4403_CR63","doi-asserted-by":"publisher","unstructured":"Wafai G, Seifert R (2025) Drug advertisements in daily newspapers: a case study with the Hannoversche Allgemeine Zeitung (Hannover General Newspaper). Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-025-04015-z","DOI":"10.1007\/s00210-025-04015-z"},{"key":"4403_CR64","doi-asserted-by":"publisher","unstructured":"Wantuch GA, Singleton J (2025) TikTok\u2019s take on side effects for glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists. J Am Pharm Assoc (2003) 102384. https:\/\/doi.org\/10.1016\/j.japh.2025.102384","DOI":"10.1016\/j.japh.2025.102384"},{"key":"4403_CR65","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"4403_CR66","unstructured":"Wollen R (2024) Everyday health. Rybelsus is ozempic in a pill \u2013 is it just as good?. Accessed: 2025, 13 March. https:\/\/www.everydayhealth.com\/diabetes\/rybelsus-is-ozempic-in-a-pill-is-it-just-as-good\/#:~:text=If%20there's%20another%20reason%20that,using%20any%20other%20oral%20medications."},{"issue":"16","key":"4403_CR67","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/DMSO.S425642","volume":"15","author":"J Xiang","year":"2023","unstructured":"Xiang J, Qin L, Zhong J, Xia N, Liang Y (2023) GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway. Diabetes Metab Syndr Obes 15(16):2433\u20132446. https:\/\/doi.org\/10.2147\/DMSO.S425642","journal-title":"Diabetes Metab Syndr Obes"},{"key":"4403_CR68","unstructured":"Zeitz Digital (2024) Unterliegen KI-generierte Inhalte heute und in Zukunft einer Kennzeichnungspflicht?. Accessed: 2025, 24 March https:\/\/www.zeitz-digital.de\/unterliegen-ki-generierte-inhalte-einer-kennzeichnungspflicht\/"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04403-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04403-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04403-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:06:25Z","timestamp":1771538785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04403-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4403"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04403-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School (\n                      \n                      ) and officially registered as a doctoral thesis project for Lara Elisabeth Propfe. The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because publicly available information is used as a data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.S. is the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of the journal for editors acting as author (https:\/\/link.springer.com\/journal\/210\/submission-guidelines#Instructions%20for%20Authors_Competing%20Interests).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}